|
US6482404B1
(en)
|
1989-10-12 |
2002-11-19 |
David James White |
Transplantation of tissue comprising a DNA sequence encoding a homologous complement restriction factor
|
|
US5866402A
(en)
*
|
1995-05-05 |
1999-02-02 |
Chiron Corporation |
Chimeric MCP and DAF proteins with cell surface localizing domain
|
|
FR2736916B1
(fr)
*
|
1995-07-21 |
1997-09-19 |
Univ Paris Curie |
Proteines hetero-multimeriques recombinantes du type alpha-beta c4bp
|
|
CA2298475A1
(en)
*
|
1997-10-31 |
1999-05-14 |
Walter Reed Army Institute Of Research |
Method of inhibiting side effects of pharmaceutical compositions containing amphiphilic vehicles or drug carrier molecules
|
|
ES2488819T3
(es)
*
|
1998-02-20 |
2014-08-29 |
Genentech, Inc. |
Inhibidores de la activación del complemento
|
|
US7112327B2
(en)
|
1998-02-20 |
2006-09-26 |
Tanox, Inc. |
Inhibition of complement activation
|
|
US6956107B2
(en)
*
|
1998-02-20 |
2005-10-18 |
Tanox, Inc. |
Inhibitors of complement activation
|
|
US6297024B1
(en)
|
1998-10-15 |
2001-10-02 |
Cell Activation, Inc. |
Methods for assessing complement activation
|
|
US6235494B1
(en)
|
1999-02-08 |
2001-05-22 |
The Scripps Research Institute |
Substrates for assessing mannan-binding protein-associated serine protease activity and methods using the substrates
|
|
WO2001032901A1
(en)
*
|
1999-11-01 |
2001-05-10 |
Chiron Corporation |
Expression vectors, transfection systems, and method of use thereof
|
|
EP2896631A1
(en)
|
2000-10-10 |
2015-07-22 |
Genentech, Inc. |
Inhibition of complement C5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection
|
|
US6820011B2
(en)
|
2001-04-11 |
2004-11-16 |
The Regents Of The University Of Colorado |
Three-dimensional structure of complement receptor type 2 and uses thereof
|
|
NZ529044A
(en)
*
|
2001-06-08 |
2008-03-28 |
Novartis Ag |
Treatment or prophylaxis of insulin-producing cell graft rejection
|
|
EP1539811A4
(en)
*
|
2002-09-16 |
2006-05-24 |
Elusys Therapeutics Inc |
PREPARATION OF BISPEQIFIC MOLECULES WITH POLYETHYLENE GLYCOL LINKER
|
|
PT1569685E
(pt)
*
|
2002-11-15 |
2012-11-02 |
Univ Colorado Regents |
Recetor do complemento 2 direcionado a moduladores do complemento
|
|
WO2005069726A2
(en)
*
|
2004-01-21 |
2005-08-04 |
Case Western Reserve University |
Hybrid and chimeric polypeptides that regulate activation of complement
|
|
PT1713503E
(pt)
*
|
2004-02-10 |
2013-11-14 |
Nat Jewish Health |
Inibição do factor b, a via alternativa do complemento e métodos relacionados
|
|
US8703693B2
(en)
*
|
2004-03-31 |
2014-04-22 |
The Feinstein Institute For Medical Research |
Adrenomedullin and adrenomedullin binding protein for ischemia/reperfusion treatment
|
|
AU2005231395B2
(en)
*
|
2004-03-31 |
2011-06-16 |
The Fernstein Institute For Medical Research |
Adrenomedullin and adrenomedullin binding protein for ischemia/reperfusion treatment
|
|
CA2610340C
(en)
*
|
2005-05-26 |
2016-02-16 |
Vernon Michael Holers |
Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
|
|
KR20180002911A
(ko)
*
|
2005-11-04 |
2018-01-08 |
제넨테크, 인크. |
안질환 치료를 위한 보체 경로 억제제의 용도
|
|
EP2044111B1
(en)
|
2006-06-21 |
2014-08-13 |
MUSC Foundation For Research Development |
Targeting complement factor h for treatment of diseases
|
|
CL2007003161A1
(es)
*
|
2006-11-02 |
2008-05-30 |
Genentech Inc |
Anticuerpos anti-factor d; acidos nucleicos que los codifican; vector y linea celular que los comprenden; metodo de produccion; composicion farmaceutica que comprende a los anticuerpos; y su uso para tratar trastornos mediados por el complemento como
|
|
JP5332064B2
(ja)
*
|
2007-03-01 |
2013-11-06 |
ウェルスタット イムノセラピューティクス， エルエルシー |
炎症により特徴付けられる疾患の治療
|
|
CA2680344A1
(en)
|
2007-03-14 |
2008-11-20 |
Woodruff Emlen |
Humaneered anti-factor b antibody
|
|
CR20170001A
(es)
|
2008-04-28 |
2017-08-10 |
Genentech Inc |
Anticuerpos anti factor d humanizados
|
|
US20090324585A1
(en)
*
|
2008-06-12 |
2009-12-31 |
The Trustees of the Leland Standford Junior University |
Complement inhibitory agents as therapeutics in posttraumatic and degenerative arthritis
|
|
WO2011003098A1
(en)
|
2009-07-02 |
2011-01-06 |
Musc Foundation For Research Development |
Methods of stimulating liver regeneration
|
|
US10239937B2
(en)
|
2009-11-05 |
2019-03-26 |
Alexion Pharmaceuticals, Inc. |
Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
|
|
CN102234332B
(zh)
*
|
2010-04-26 |
2014-12-17 |
浙江海正药业股份有限公司 |
一种重组人血白蛋白及其融合蛋白的分离纯化工艺
|
|
CN103038252A
(zh)
|
2010-05-14 |
2013-04-10 |
科罗拉多大学董事会,法人团体 |
改良的补体受体2(cr2)靶向群
|
|
WO2011163412A1
(en)
|
2010-06-22 |
2011-12-29 |
The Regents Of The University Of Colorado, A Body Corporate |
Antibodies to the c3d fragment of complement component 3
|
|
BR112013005116A2
(pt)
|
2010-09-03 |
2019-09-24 |
Stem Centrx Inc |
moduladores e métodos de uso
|
|
US10039802B2
(en)
|
2011-06-22 |
2018-08-07 |
Apellis Pharmaceuticals, Inc. |
Methods of treating chronic disorders with complement inhibitors
|
|
AU2013243570B2
(en)
|
2012-04-03 |
2017-12-14 |
Novelmed Therapeutics, Inc. |
Humanized and chimeric anti-factor Bb antibodies and uses thereof
|
|
US9803005B2
(en)
|
2012-05-24 |
2017-10-31 |
Alexion Pharmaceuticals, Inc. |
Humaneered anti-factor B antibody
|
|
JP2015535212A
(ja)
|
2012-08-17 |
2015-12-10 |
ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト |
補体活性化を検出するための組成物および方法
|
|
US10413620B2
(en)
|
2012-08-17 |
2019-09-17 |
The Regents Of The University Of Colorado, A Body Corporate |
Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
|
|
BR112016002845A2
(pt)
|
2013-08-12 |
2017-09-12 |
Genentech Inc |
composições e métodos para tratar condições associadas ao complemento
|
|
SG10202104175YA
(en)
|
2014-02-27 |
2021-06-29 |
Allergan Inc |
COMPLEMENT FACTOR Bb ANTIBODIES
|
|
EP3137503A1
(en)
|
2014-05-01 |
2017-03-08 |
Genentech, Inc. |
Anti-factor d antibody variants and uses thereof
|
|
JP2018503368A
(ja)
|
2014-12-18 |
2018-02-08 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
Ｃｄｃを誘発する抗体を決定するためのアッセイ法および方法
|
|
IL296929B2
(en)
*
|
2015-09-24 |
2025-07-01 |
Univ Pennsylvania |
Composition and method for treating complement-mediated disease
|
|
WO2017075252A1
(en)
|
2015-10-30 |
2017-05-04 |
Genentech, Inc. |
Anti-factor d antibody variant conjugates and uses thereof
|
|
JP2018534930A
(ja)
|
2015-10-30 |
2018-11-29 |
ジェネンテック， インコーポレイテッド |
抗ｄ因子抗体及びコンジュゲート
|
|
LT3394089T
(lt)
*
|
2015-12-23 |
2021-11-25 |
eleva GmbH |
Polipeptidai, skirti komplemento aktyvacijos inhibicijai
|
|
DK3474883T3
(da)
|
2016-06-28 |
2022-08-29 |
Univ Ulm |
Komplementinhibitorer og anvendelser deraf
|
|
GB201800620D0
(en)
|
2018-01-15 |
2018-02-28 |
Univ Manchester |
C3b Binding Polypeptide
|
|
EP3956347A4
(en)
*
|
2019-04-13 |
2023-09-20 |
National Centre For Cell Science |
DAF-MCP CHIMERIC PROTEINS, THEIR MANUFACTURING METHOD AND USE OF THE CHIMERIC PROTEIN TO TREAT PATHOLOGICAL CONDITIONS INVOLVING THE COMPLEMENT SYSTEM
|